Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Macrogenics (NASDAQ:MGNX) but lowers the price target from $14 to $9.
July 29, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Macrogenics but lowers the price target from $14 to $9.
The lowered price target from $14 to $9 suggests a less optimistic outlook for Macrogenics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100